| Literature DB >> 32714535 |
Ryota Otoshi1, Akimasa Sekine1, Koji Okudela2, Masato Asaoka1, Yozo Sato1, Satoshi Ikeda1, Tomohisa Baba1, Shigeru Komatsu1, Eri Hagiwara1, Takashi Ogura1.
Abstract
The present report describes a case of a 68-year-old male patient with epidermal growth factor receptor (EGFR)-mutant non-small cell lung carcinoma (NSCLC). After cytotoxic chemotherapy of three regimens following 22 months of treatment with EGFR-tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, the patient underwent S-1 treatment. Despite a decrease in carcinoembryonic antigen 1 month after initiating S-1 treatment, the patient developed cardiac tamponade. The evaluation of pericardial effusion confirmed small-cell lung carcinoma (SCLC) transformation. Subsequently, a combination therapy of carboplatin and etoposide was administered, which led to a marked improvement in imaging. In patients with NSCLC who develop pericardial effusion after long-term EGFR-TKI therapy, including osimertinib treatment, it is important to investigate whether SCLC transformation occurs or not as a treatable entity. Copyright: © Otoshi et al.Entities:
Keywords: adenocarcinoma; epidermal growth factor receptor; osimertinib; pericardial effusion; small-cell lung carcinoma transformation
Year: 2020 PMID: 32714535 PMCID: PMC7366234 DOI: 10.3892/mco.2020.2059
Source DB: PubMed Journal: Mol Clin Oncol ISSN: 2049-9450